Japan Tobacco Licenses Osteoporosis Drug To Merck
This article was originally published in PharmAsia News
You may also be interested in...
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
MedImmune Gains Anti-CD28 Biologic In Deal With Japan Tobacco
MedImmune is bolstering its research pipeline for treatments targeting inflammatory diseases, announcing its second licensing deal this month for technology in the therapeutic class. Under the latest deal with Japan Tobacco, announced Dec. 28, the company intends to develop a monoclonal antibody targeting CD28 receptor pathways for treatment of inflammatory diseases